Brief: Polypid Announces Scheduling Of Type D Meeting With U.S. FDA
12/12/2022 15:18
Dec 12 (Reuters) - PolyPid Ltd PYPD.O :
* POLYPID ANNOUNCES SCHEDULING OF TYPE D MEETING WITH U.S.
FDA TO
DISCUSS SHIELD I PHASE 3 RESULTS AND REGULATORY PATHWAY FOR
D-PLEX₁₀₀ FOR THE PREVENTION OF SURGICAL SITE INFECTIONS IN
ABDOMINAL COLORECTAL SURGERY
Source text for Eikon: ID:nGNX4rSMDk
Further company coverage: PYPD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA